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Abstract 
Background: Men who have sex with men (MSM) are recommended the Human 
Papillomavirus (HPV) vaccination due to their higher risk of genital warts and anal cancer. 
Purpose: To examine HPV vaccine acceptability amongst MSM in the UK. Methods: Using 
advertisements via Facebook, MSM were recruited to an online survey measuring 
motivations for HPV vaccination. Logistic regression was performed to identify predictors of 
HPV vaccine acceptability. Results: Out of 1508 MSM (median age = 22, range: 14–63 
years) only 19% had good knowledge of HPV. Overall, 55% of MSM were willing to ask for 
the HPV vaccine and 89% would accept it if offered by a healthcare professional (HCP). 
Access to sexual health clinics (SHCs) [OR = 1.82, 95% CI 1.29–2.89], the disclosure of 
sexual orientation to a HCP [OR = 2.02, CI 1.39–3.14] and HIV-positive status [OR = 1.96, 
CI 1.09–3.53] positively predicted HPV vaccine acceptability. After receiving information 
about HPV, perceptions of HPV risk [OR = 1.31, CI 1.05–1.63], HPV infection severity [OR 
= 1.89, CI 1.16–3.01), HPV vaccination benefits [OR = 1.61, CI 1.14–3.01], HPV vaccine 
effectiveness [OR = 1.54, CI 1.14–2.08], and the lack of perceived barriers to HPV 
vaccination [OR = 4.46, CI 2.95–6.73] were also associated with acceptability. 
Conclusions: Although nearly half of MSM would not actively pursue HPV vaccination, the 
vast majority would accept the vaccine if recommended by HCPs. In order to achieve optimal 
uptake, vaccine promotion campaigns should focus on MSM who do not access SHCs and 
those unwilling to disclose their sexual orientation.
3 
INTRODUCTION 
 Vaccination against human papillomavirus (HPV), which is a common sexually 
transmitted infection (STI) protects associated genital warts as well as anogenital and oral 
cancers.[1]. From 2007, many developed countries introduced a female-oriented HPV 
vaccination strategy focussing on the prevention of cervical cancer. Data from Australia 
showed that high coverage of female-oriented vaccination could result in a parallel decline of 
the virus in unvaccinated heterosexual men of corresponding age, indicating that this strategy 
is capable of “herd protection”.[2] However, this strategy is unlikely to protect men who have 
sex outside of the vaccinated “herd”, such as men who have sex with men (MSM). In 
Australia, gender-neutral vaccination of adolescents at schools began in 2012 and a recent 
analysis  indicated that additional targeted vaccination of MSM would also be beneficial and 
cost-effective.[3] In England, female-oriented HPV vaccination has consistently achieved 
85% coverage and due to little clinical benefit of adding boys to HPV vaccination, the UK’s 
Joint Committee on Vaccination and Immunisation (JCVI) decided against a gender-neutral 
HPV vaccination strategy but recommended targeted HPV vaccination of MSM below the 
age of 46 years.[4,5]  
 MSM are at substantial risk of HPV-related diseases. Female-oriented HPV 
vaccination without an MSM-targeted approach is likely to increase health inequalities, as the 
rates of genital warts will decline in heterosexual populations, but not MSM.[3] HPV is very 
common amongst MSM, increasing the chances of acquiring HIV.[6] HIV-positive MSM are 
at substantially higher risk of anal cancer due to HPV, even after the introduction of highly 
active antiretroviral therapy (78 per 100 000 men).[7] Although most MSM would acquire at 
least one HPV type while being sexually active, the HPV vaccine protects against multiple 
HPV types, therefore reducing opportunities for further transmission.  
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HPV vaccine acceptability  
A lack of motivation towards the HPV vaccine could compromise the effectiveness of an 
MSM-targeted approach. There is evidence that MSM can be highly receptive to HPV 
vaccination, especially those who know about the virus and perceive themselves at risk of 
infection.[8] Although MSM in the UK have generally positive attitudes towards vaccinations 
against STIs, they do not perceive themselves at particular risk of HPV and its associated 
diseases.[9] MSM consider HPV to be mainly ‘a female’ issue relating to cervical cancer; 
thus suggesting that they might not perceive HPV vaccination as an urgent preventative 
intervention. Four fifths of MSM recruited in a London clinic expressed willingness to 
receive the vaccine[10]. However, MSM living outside of the capital might be less likely to 
access SH clinics or disclose sexuality to a healthcare professional (HCP), factors likely to be 
associated with vaccination uptake.  Hence, the aim of this study was to identify factors 
associated with HPV vaccine acceptability in MSM in the UK nationwide.  
 
METHODS 
Design and Participants 
 The present study was a cross-sectional online survey exploring HPV vaccine 
acceptability. Demographic, behavioural and psychological factors were measured to identify 
correlates of HPV vaccine acceptability. Participants were self-identified gay, bisexual and 
other MSM over 16 years of age. The study used an online convenience sampling method to 
recruit men from various parts of the UK in order to gather views from MSM living in a 
variety of rural and urban areas. Participants, who were born outside of the UK and resident 
overseas, were excluded from the study because of their limited relevance to MSM-targeted 
HPV vaccination in the UK. All cisgender women, and self-identified heterosexual men with 
no experience of sexual intercourse with other men, were also excluded from the analysis. 
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Recruitment and Procedure 
 Between July and September 2015, an advertisement was used to publicise the online 
survey using the Facebook social media platform. The advert encouraged MSM to take part 
in the study by offering an entry into a prize draw worth £75. The advertisement strategy was 
set to be shown to men, aged 16-26 years old, who lived in the UK and declared their interest 
in other men, as specified on their Facebook profiles. Additionally, the participants were 
encouraged to invite their gay and bisexual male friends to take part in the survey by sharing 
the study advert. 
 Once potential participants clicked on the Facebook advert, they were redirected to 
the online survey and were presented with an information and consent page describing the 
purpose of the study, confidentiality and participants’ right to withdraw at any time.  Finally, 
participants were shown links to health charities for MSM should they have any concerns or 
further questions.  
 
Measurements 
 The survey included 64 items. HPV vaccine acceptability was measured using a 
seven-item scale, developed from the results of a qualitative study about HPV vaccination for 
MSM (Nadarzynski et al., 2017). It reflected individual motivation and preparedness to 
initiate and complete the HPV vaccination course. Participants were asked to estimate the 
likelihood of performing seven activities related to HPV vaccination by choosing one of five 
responses ranging from “very unlikely” to “very likely”. A composite score was calculated by 
averaging responses from these seven activities. The scale demonstrated good internal 
consistency in our sample (α=0.90). 
 Eleven single items assessed socio-demographic characteristics (i.e. age, gender 
identity, sexual identity, educational attainment, ethnicity, country of origin, country of 
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residence and size of settlement, relationship status, participation in the gay scene, usage of 
mobile phone dating applications). These were adopted from the Office for National Statistics 
(ONS; 2015) and the European MSM Internet Survey (EMIS; Weatherburn et al., 2013). Four 
single items, adopted from EMIS, assessed behavioural risk indicators of HPV infection risk 
(i.e. age of sexual debut, lifetime number of sexual partners, sexual role during anal sex, and 
frequency of anal intercourse in the last 12 months). Eight single items, adopted from EMIS, 
assessed access to healthcare (i.e. settings and uptake of STI screening, previous STI 
diagnosis, last HIV test, HIV status, sexual orientation disclosure to an HCP and the age of 
disclosure). Two items, adopted from EMIS, assessed hepatitis A and B status, examining 
uptake and schedule completion. HPV knowledge was measured using a single perceived 
knowledge question and a scale specifically developed for this study with eleven true/false 
statements. Five psychological constructs were measured: comparative risk perceptions of 
HPV-related diseases, perceived benefits and barriers to HPV vaccination, perceived HPV 
vaccine effectiveness and vaccine hesitancy, all showing good internal consistency (α>0.80). 
Information about psychological measurements are available from the corresponding author.  
 
Data analysis 
HPV vaccine acceptability scores were transformed into a four category ordinal variable 
(strongly unacceptable/unacceptable/acceptable/strongly acceptable). Multifactorial ordinal 
regression models were performed with demographic, behavioural and psychological 
exploratory factors. Significant variables were then entered into a multifactorial regression 
model for goodness-of-fit analysis and adjustment. Odds ratios with 95% confidence intervals 
were calculated to represent the significant associations.  
 
RESULTS 
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Sample characteristics 
 In total, 1508 participants completed HPV vaccine acceptability measures. The 
median age was 22 years (range: 14-63), 93% self-identified as gay and 5% as bisexual (see 
supplementary Table A). The majority (85%) were born in the UK, 87% lived in England, 
92% were White, and 61% reported being single. Around 43% had visited gay venues (e.g. 
bar, pub or club) and 47% reported using dating websites or mobile applications to meet other 
men at least once a month. The median age of first same-sex sexual intercourse was 16 
(range: 8-41), and amongst sexually active men, 39% reported having up to 10-lifetime 
sexual partners. The majority (79%) reported engaging in receptive anal intercourse with 
frequencies ranging from 1-2 times (19%) to more than 50 times (11%) in the last 12 months. 
A third of the sample reported never being tested for an STI at an SH clinic. The median age 
of the first SH screening was 19 years (range: 13-48). Approximately 26% of participants had 
not disclosed their same-sex experiences to an HCP. Amongst men who had disclosed, the 
median age of disclosure was 19 years (range: 13-50). Overall, 27% and 49% of the sample 
reported completing hepatitis A and B vaccinations, respectively.   
 
HPV vaccine acceptability 
 Figure 1 outlines the responses to each item of the HPV vaccine acceptability 
measurement. Overall, 83% of MSM would be willing to receive the HPV vaccine (mean = 
3.94, SD=0.91, median=4, interquartile range: 3.4-4.7). Responses to each vaccination 
behaviour variable is presented in figure 1.    
Factors associated with HPV vaccine acceptability 
 Table 1 presents socio-demographic associations of HPV vaccine acceptability. 
Characteristics such as being younger than 18, born in the UK, of non-White ethnic origin, 
and living in either a small town or a village were associated with lower HPV vaccine 
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acceptability. MSM that had never visited gay venues or had not used online apps/websites to 
meet other men also reported lower levels of HPV vaccine acceptability. The participants who 
reported higher numbers of lifetime sexual partners and engaged more frequently in receptive 
anal intercourse showed higher levels of HPV vaccine acceptability. MSM that had disclosed 
their sexual orientation to a HCP, had previously visited an SH clinic for STI screening and 
had previously received the hepatitis vaccination were more likely to accept the HPV 
vaccine. Additionally, men who had tested for HIV in the previous six months, or had been 
diagnosed with an STI or were HIV-positive, reported higher levels of HPV vaccine 
acceptability. Participants with good knowledge about HPV were also more likely to accept 
the HPV vaccine.  
 Table 2 shows that comparative risk perceptions, perceived seriousness of HPV 
infection and related diseases, perceived benefits and barriers to HPV vaccination, perceived 
HPV vaccine effectiveness and vaccine hesitancy were significantly associated with HPV 
vaccine acceptability. The multifactorial ordinal regression showed that all psychological 
variables, excluding vaccine hesitancy, were associated with HPV vaccine acceptability, with 
perceived barriers being the strongest correlate.  
 
DISCUSSION 
 This study shows that while half of MSM might be unlikely to actively seek the HPV 
vaccine, nearly all would be willing to accept it if offered by a HCP. MSM face multiple 
barriers to HPV vaccination such as the difficulty with accessing SH clinics and openly 
discussing their sexuality. We have observed a trend in which younger MSM, living outside 
of urban areas, who do not participate in their gay community/socio-sexual networks and 
have restricted access to SH services are less likely to accept the HPV vaccine. Also, men 
who perceived numerous barriers and did not see HPV vaccine as beneficial saw themselves 
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less likely to receive the vaccine. Therefore, HPV vaccination programmes for MSM in the 
UK need to reduce these barriers to increase motivation towards the vaccine and overall 
uptake rates.  
 Similar HPV vaccine acceptability rates had been reported in other developed 
countries such as Sweden (79%)[11], the USA (86%, 74%)[12, 13], and Italy (89%)[14]. This 
study also supports the findings of King et al. (2015)[10] which concluded that 83% of MSM 
in London would find HPV vaccine acceptable. The high acceptability rate could be 
explained by general positive attitudes of UK MSM towards STI prevention, including 
vaccinations.[9] However, the contrast in the virtual HPV vaccine acceptability and actual 
suboptimal completion of hepatitis A and B vaccination we observe in our study suggests 
MSM face other substantial barriers to vaccinations. Although investigation of the reasons for 
the suboptimal uptake of hepatitis A and B vaccinations were not within this project’s scope, 
these rates could be indicative of the future actual HPV vaccination initiation and completion 
rates amongst young MSM. 
 Our study identified multiple factors associated with HPV vaccine acceptability in 
MSM. These factors are consistent with previous research of Reiter et al. (2010)[15] and 
Meites et al. (2014)[16] who showed that MSM, who were at the beginning of their sexual 
activity, reported lower number of sexual partners and were less likely to accept the vaccine. 
It is possible that these men have poor knowledge about STIs due to their limited access to 
socio-sexual networks and SH services, thus may not perceive themselves at risk of STIs, 
including HPV. An analysis of attendances demonstrated that approximately 374,983 MSM 
utilised SH clinics in England [17], which accounts for 45% of the estimated size of the 
MSM population by Public Health England (830,558 MSM) [18]. If only half of MSM access 
SH clinics and about 60% of those are willing to disclose same-sex behaviours, then the 
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majority of MSM will remain unvaccinated. Therefore, in order to eradicate the virus in the 
MSM population alternative vaccination strategies might need to be considered.  
 
Strengths and limitations 
 While there is no agreed measure of acceptability, this study utilised a 7-item scale, 
with excellent internal consistency, to better understand the motivation for HPV vaccination 
amongst MSM. This study used an online recruitment method to reach young, geographically 
dispersed MSM. The characteristics of this sample are considered to be highly relevant in 
MSM-targeted HPV vaccination, as a third of the sample reported having less than six 
lifetime sexual partners and 65% were below the age of 26 years. Although this study relied 
on a convenience sampling method through Facebook advertisement, the study was 
advertised nationally and may represent views of a diverse group of MSM. Although it is 
impossible to specify the representativeness of the sample, several studies have highlighted 
the benefit of using social media to recruit MSM.[19] Moreover, one analysis demonstrated 
that there were no differences in the demographic and behavioural characteristics of MSM 
recruited via conventional sampling methods in various gay-oriented spaces and those 
recruited via Facebook.[20] Our study used a specific sampling quota targeting only men who 
disclosed their interest in men, suggesting they were already comfortable disclosing their 
sexuality online. Thus, the generalizability of these findings is limited. There is a possibility 
that HPV vaccine acceptability could differ amongst younger MSM who are not yet ready to 
disclose their sexual orientation. Also, the self-reported data are subject to recall bias and 
social desirability; it is possible that some participants incorrectly reported vaccination 
history for HPV or hepatitis, and falsely estimated the age of sexual debut or the number of 
lifetime sexual partners.  
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Conclusion 
 Poor awareness and lack of perceived demand for the HPV vaccine could delay 
vaccine uptake, reducing the effectiveness of an MSM-targeted HPV vaccination. Active 
promotion and recommendation of the vaccine by HCPs is essential to achieving optimal 
uptake. MSM at the beginning of their same-sex activity, who face multiple barriers to 
accessing SH services and who are the most relevant for the HPV vaccination might be less 
likely to receive it. If HPV vaccination cannot reach these men, the overall cost-effectiveness 
of the programme will be compromised. This will require the provision of alternative settings 
for vaccination of young men still unsure of their sexual orientation.  
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